Neuraxis

Neuraxis Gross Profit/Assets

The Gross Profit to Assets Ratio of Neuraxis (NRXS) as of Nov 22, 2026 is 46.94 %. In the previous year, Gross Profit to Assets Ratio was 48.85 % — a change of -3.89% (lower).

Gross Profit/Assets

46.94 %

YoY

-3.89%

Last updated:

Gross Profit to Assets Ratio of Neuraxis is 2025 46.94 % . Gross Profit to Assets Ratio of Neuraxis was 2024 48.85 % . It decreases by -3.89% lower compared to the previous year.

The Neuraxis Gross Profit/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Profit/Assets
Date
Gross Profit/Assets
Jan 1, 2020
51.95 USD
Jan 1, 2021
296.34 USD
Jan 1, 2022
161.26 USD
Jan 1, 2023
423.30 USD
Jan 1, 2024
48.85 USD
Jan 1, 2025
46.94 USD
The Neuraxis Gross Profit/Assets history
YEARGross Profit/AssetsYoY
46.94 %-3.89%
48.85 %-88.46%
423.30 %+162.50%
161.26 %-45.58%
296.34 %+470.45%
51.95 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuraxis Stock analysis

What does Neuraxis do? NeurAxis, Inc. generates revenue through the development and commercialization of neuromodulation therapies targeting chronic conditions in pediatric patients. The company's primary product, the B-Stim device, is designed for functional abdominal pain associated with irritable bowel syndrome (IBS) and functional nausea in children aged 11-18. The FDA pipeline includes additional indications such as chronic nausea, post-concussion syndrome, chemotherapy-induced nausea and vomiting, and cyclic vomiting syndrome, which expand the potential market reach of their PENFS technology. The company's focus on pediatric applications differentiates its offerings within the neuromodulation sector. The Percutaneous Electrical Nerve Field Stimulation (PENFS) technology underpins both the B-Stim and IB-Stim systems, which are specifically tailored for pediatric use. These devices are intended for patients 11-18 years of age with functional abdominal pain linked to IBS, positioning NeurAxis to address unmet medical needs in adolescent healthcare. The FDA's involvement in the pipeline process ensures regulatory alignment for expanding indications, which supports market adoption and potential revenue streams. NeurAxis targets healthcare providers and pediatric specialists who treat chronic conditions in adolescents. The company's products are positioned to address functional gastrointestinal disorders and related symptoms, offering an alternative to traditional pharmacological treatments. By focusing on specific age groups and medical indications, NeurAxis aims to capture a niche segment within the broader neuromodulation market. Neuraxis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuraxis stock

Gross Profit to Assets Ratio of Neuraxis is 46.94 % in 2025.

Gross Profit to Assets Ratio of Neuraxis changed from 48.85 % to 46.94 %, representing a -3.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit to Assets Ratio Neuraxis since 2006 – with annual values, charts, and detailed analysis.

Gross Profit/Assets measures how efficiently a company uses its assets to generate gross profit. Research shows it is a strong predictor of future stock returns.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Profit to Assets Ratio's Neuraxis with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Profit to Assets Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Profit to Assets Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Neuraxis

All Key Metrics — Neuraxis